Gregory Merrick is an Oncology physician affiliated with Wheeling Jesuit University. OpenAlex indexes 9 publications with 321 citations (h-index 6); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1 Medical Park
Wheeling, WV 260036379
Telephone
304-243-3490Registry record last updated 14 Aug 2012.
Clinical trials
- Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial
Sponsor: Schiffler Cancer Center
- Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial
Sponsor: Schiffler Cancer Center
- Low Dose Supplemental External Radiation With Pd-103 Versus Pd-103 Alone for Prostate Cancer
Sponsor: Schiffler Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Theragenics CorporationProgram year20258 payments$10,281openpaymentsdata.cms.gov ↗
- Theragenics CorporationProgram year20246 payments
- Theragenics CorporationProgram year20222 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2021)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Genitourinary & hormones
92%alpha-Adrenergic Blocker69.9%Tamsulosin Hcl97%Terazosin Hcl2%Silodosin2%Part D<11 patients5-alpha Reductase Inhibitor13.7%Dutasteride57%Finasteride43%Part D≥40 patients+ 2 more classes in this area
Metabolism & gastrointestinal
4%Corticosteroid3.1%Prednisone100%Part D≥11 patientsProton pump inhibitor0.9%Omeprazole100%Part D<11 patientsCancer & immunology
3.9%Cytochrome P450 17A1 Inhibitor1.4%Abiraterone Acetate100%Part D<11 patientsAndrogen Receptor Inhibitor1.4%Xtandi100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Effect of Body Mass Index on Intrafraction Prostate Displacement Monitored by Real-Time Electromagnetic Tracking
International Journal of Radiation Oncology*Biology*Physics
2012
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”